Neurodegeneration in diabetic retinopathy: Current concepts and therapeutic implications

Cheung, 2010, Diabetic retinopathy, Lancet, 376, 124, 10.1016/S0140-6736(09)62124-3 Yau, 2012, Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care, 35, 556, 10.2337/dc11-1909 Antonetti, 2012, Diabetic retinopathy, N Engl J Med, 366, 1227, 10.1056/NEJMra1005073 Simó, 2012, Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications, Br J Ophthalmol, 96, 1285, 10.1136/bjophthalmol-2012-302005 Simó, 2014, Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives, Trends Endocrinol Metab, 25, 23, 10.1016/j.tem.2013.09.005 Mohamed, 2007, Management of diabetic retinopathy: a systematic review, JAMA, 298, 902, 10.1001/jama.298.8.902 Simó, 2009, Advances in the medical treatment of diabetic retinopathy, Diabetes Care, 32, 1556, 10.2337/dc09-0565 Do, 2013, Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment, JAMA Ophthalmol, 131, 139, 10.1001/2013.jamaophthalmol.91 Brown, 2013, Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE, Ophthalmology, 120, 2013, 10.1016/j.ophtha.2013.02.034 Zechmeister-Koss, 2012, Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review, Br J Ophthalmol, 96, 167, 10.1136/bjophthalmol-2011-300674 Simó, 2008, Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy, Diabetologia, 51, 1574, 10.1007/s00125-008-0989-9 Joussen, 2007, Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema, Dev Ophthalmol, 39, 69, 10.1159/000098500 Carrasco, 2007, Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration, Diabetes Care, 30, 2902, 10.2337/dc07-0332 Carrasco, 2008, Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation, Mol Vis, 4, 1496 Garcia-Ramírez, 2009, Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy, Diabetologia, 52, 2633, 10.1007/s00125-009-1548-8 Lopes de Faria, 2002, Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy, Br J Ophthalmol, 86, 725, 10.1136/bjo.86.7.725 van Dijk, 2010, Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes, Invest Ophthalmol Vis Sci, 51, 3660, 10.1167/iovs.09-5041 van Dijk, 2011, Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy, Vision Res, 28, 244 van Dijk, 2009, Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy, Invest Ophthalmol Vis Sci, 50, 3404, 10.1167/iovs.08-3143 Valverde, 2013, Proapoptotic and survival signaling in the neuroretina at early stages of diabetic retinopathy, Mol Vis, 19, 47 Mizutani, 1998, Müller cell changes in human diabetic retinopathy, Diabetes, 47, 445, 10.2337/diabetes.47.3.445 Bringmann, 2012, Müller glial cells in retinal disease, Ophthalmologica, 227, 1, 10.1159/000328979 Di Leo, 1990, Spatial frequency-selective losses with pattern electroretinogram in type 1 (insulin-dependent) diabetic patients without retinopathy, Diabetologia, 33, 726, 10.1007/BF00400342 Di Leo, 1994, Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy, Diabetologia, 37, 911, 10.1007/BF00400947 Shirao, 1998, Electrical responses from diabetic retina, Prog Retin Eye Res, 17, 59, 10.1016/S1350-9462(97)00005-0 Ewing, 1998, Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision, Endocr Rev, 19, 462, 10.1210/edrv.19.4.0340 Bearse, 2006, A multifocal electroretinogram model predicting the development of diabetic retinopathy, Prog Retin Eye Res, 25, 425, 10.1016/j.preteyeres.2006.07.001 Bronson-Castain, 2009, Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation, Retina, 29, 618, 10.1097/IAE.0b013e31819a988b Han, 2004, Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy, Invest Ophthalmol Vis Sci, 45, 4106, 10.1167/iovs.04-0405 Harrison, 2011, Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes, Invest Ophthalmol Vis Sci, 52, 772, 10.1167/iovs.10-5931 Ng, 2008, Local diabetic retinopathy prediction by multifocal ERG delays over 3 years, Invest Ophthalmol Vis Sci, 49, 1622, 10.1167/iovs.07-1157 Lecleire-Collet, 2011, Evaluation of retinal function flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy, Invest Ophthalmol Vis Sci, 52, 2861, 10.1167/iovs.10-5960 Tyrberg, 2011, Electrophysiological studies in newly onset type 2 diabetes without visible vascular retinopathy, Doc Ophthalmol, 123, 193, 10.1007/s10633-011-9298-6 Riva, 2005, Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina, Prog Retin Eye Res, 24, 183, 10.1016/j.preteyeres.2004.07.002 Lieth, 1998, Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy, Penn State Retina Research Group Diabetes, 47, 815 Lieth, 2000, Diabetes reduces glutamate oxidation and glutamine synthesis in the retina, Penn State Retina Research Group Exp Eye, 70, 723 Kowluru, 2001, Retinal glutamate in diabetes and effect of antioxidants, Neurochem Int, 38, 385, 10.1016/S0197-0186(00)00112-1 Ambati, 1997, Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy, Arch Ophthalmol, 115, 1161, 10.1001/archopht.1997.01100160331011 Pulido, 2007, A role for excitatory amino acids in diabetic eye disease, Exp Diabetes Res, 2007, 36150, 10.1155/2007/36150 Ng, 2004, Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats, Brain Res, 1018, 66, 10.1016/j.brainres.2004.05.055 Santiago, 2009, Diabetes changes the levels of ionotropic glutamate receptors in the rat retina, Mol Vis, 15, 1620 Li, 2002, Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells, Invest Ophthalmol Vis Sci, 43, 3109 Brownlee, 2005, The pathobiology of diabetic complications: a unifying mechanism, Diabetes, 54, 1615, 10.2337/diabetes.54.6.1615 Giroti, 2004, Role of hydroxiperoxides in photo-oxidative stress signalling, Antioxid Redox Signal, 6, 301, 10.1089/152308604322899369 Xiao, 2012, Physiological effects of superoxide dismutase on altered visual function of retinal ganglion cells in db/db mice, PLoS ONE, 7, e, 10.1371/journal.pone.0030343 Fukumoto, 2012, Vulnerability of the retinal microvasculature to oxidative stress: ion channel-dependent mechanisms, Am J Physiol Cell Physiol, 302, C1413, 10.1152/ajpcell.00426.2011 Simó, 2006, Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy, Curr Diabetes Rev, 2, 71, 10.2174/157339906775473671 Barnstable, 2004, Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential, Prog Retin Eye Res, 23, 561, 10.1016/j.preteyeres.2004.05.002 Simó, 2002, Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy, Diabetes Care, 25, 2282, 10.2337/diacare.25.12.2282 Simó, 2007, Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema, Diabetes Care, 30, 725, 10.2337/dc06-1345 Hernández, 2005, Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects, Diabetes Care, 28, 1941, 10.2337/diacare.28.8.1941 Gonzalez-Fernandez, 2003, Interphotoreceptor retinoid-binding protein – an old gene for new eyes, Vis Res, 43, 3021, 10.1016/j.visres.2003.09.019 Wu, 2007, Interphotoreceptor retinoid-binding protein is the physiologically relevant carrier that removes retinol from rod photoreceptor outer segments, Biochemistry, 24, 8669, 10.1021/bi7004619 Gonzalez-Fernandez, 2008, Focus on molecules: interphotoreceptor retinoid binding protein (IRBP), Exp Eye Res, 86, 169, 10.1016/j.exer.2006.09.003 Liou, 1998, Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid binding protein gene, J Neurosci, 18, 4511, 10.1523/JNEUROSCI.18-12-04511.1998 Narfström, 1989, Reduced level of interphotoreceptor retinoid binding protein (IRBP), a possible cause fro retinal degeneration in the Abyssinian cat, Cell Tissue Res, 257, 631, 10.1007/BF00221474 Wiggert, 1994, An early decreased in gene expression in Abyssinian cats homozygous for hereditary rod-cone degeneration, Cell Tissue Res, 278, 291, 10.1007/BF00414173 Ripps, 2000, The rhodopsin cycle is preserved in IRBP knockout mice despite abnormalities in retinal structure and fuction, Vis Neurosci, 17, 97, 10.1017/S095252380017110X den Hollander, 2009, A homozygous missesnse mutation in the IRBP gene (RBP3) associated with aurosomal recessive retinitis pigmentosa, Invest Ophthalmol Vis Sci, 50, 1864, 10.1167/iovs.08-2497 Marneros, 2005, Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function, Am J Pathol, 167, 1451, 10.1016/S0002-9440(10)61231-X García-Ramírez, 2008, Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects, Diabetes Care, 31, 1189, 10.2337/dc07-2075 Jin, 2000, Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia, Proc Natl Acad Sci USA, 97, 10242, 10.1073/pnas.97.18.10242 Saint-Geniez, 2008, Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors, PLoS ONE, 3, e3554, 10.1371/journal.pone.0003554 Nishijima, 2007, Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptative response ischemic injury, Am J Pathol, 171, 53, 10.2353/ajpath.2007.061237 Bai, 2009, Müller cell-derived VEGF is a significant contributor to retinal neovascularization, J Pathol, 219, 446, 10.1002/path.2611 Miki, 2010, Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells, J Cell Physiol, 224, 262 Becerra, 2002, Erythropoietin: an endogenous retinal survival factor, N Engl J Med, 347, 1968, 10.1056/NEJMcibr022629 Rex, 2009, Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse, Exp Eye Res, 89, 735, 10.1016/j.exer.2009.06.017 Shen, 2010, ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD, Invest Ophthalmol Vis Sci, 5, 35, 10.1167/iovs.09-3544 Hernández, 2006, Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema, Diabetes Care, 29, 2028, 10.2337/dc06-0556 Chen, 2008, Erythropoietin deficiency decreases vascular stability in mice, J Clin Invest, 118, 526 García-Arumí, 2009, Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema, Eye, 23, 1066, 10.1038/eye.2008.230 Grant, 2008, Erythropoietin: when liability becomes asset in neurovascular repair, J Clin Invest, 118, 467 Joussen, 2004, A central role for inflammation in the pathogenesis of diabetic retinopathy, FASEB J, 18, 1450, 10.1096/fj.03-1476fje Tang, 2011, Inflammation in diabetic retinopathy, Prog Retin Eye Res, 30, 343, 10.1016/j.preteyeres.2011.05.002 Gerhardinger, 2005, Expression of acute-phase response proteins in retinal Müller cells in diabetes, Invest Ophthalmol Vis Sci, 41, 1971 Zhong, 2012, Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cell-derived inflammatory cytokine production in diabetes, Diabetes, 61, 492, 10.2337/db11-0315 Zong, 2010, Hyperglycemia-induced proinflammatory reponses by retinal Müller glia are regulated by receptor for advanced glycation end-products (RAGE), Diabetologia, 53, 2656, 10.1007/s00125-010-1900-z Berner, 2012, Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology, Diabetologia, 55, 845, 10.1007/s00125-011-2393-0 Barber, 2011, The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy, Invest Ophthalmol Vis Sci, 52, 1156, 10.1167/iovs.10-6293 Wilkinson-Berka, 2006, Angiotensin and diabetic retinopathy, Int J Biochem Cell Biol, 38, 752, 10.1016/j.biocel.2005.08.002 Downie, 2008, AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxigen-induced retinopathy, Glia, 56, 1076, 10.1002/glia.20680 Kurihara, 2008, Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina, Diabetes, 57, 2191, 10.2337/db07-1281 Silva, 2009, Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes, Diabetes, 58, 1382, 10.2337/db09-0166 Formaz, 1997, Diffuse luminance flicker increases retinal vessel diameter in humans, Curr Eye Res, 16, 1252, 10.1076/ceyr.16.12.1252.5021 Metea, 2007, Signalling within the neurovascular unit in the mammalian retina, Exp Physiol, 92, 635, 10.1113/expphysiol.2006.036376 Nguyen, 2009, Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy, Diabetes Care, 32, 2075, 10.2337/dc09-0075 Sasaki, 2010, Nurodegenerative influence of oxidative stress in the retina of a murine model of diabetes, Diabetologia, 53, 971, 10.1007/s00125-009-1655-6 Barba, 2010, Metabolic fingerprints of proliferative diabetic retinopathy: an 1H-NMR-based metabonomic approach using vitreous humor, Invest Ophthalmol Vis Sci, 51, 4416, 10.1167/iovs.10-5348 Zhang, 2008, Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes, Invest Ophthalmol Vis Sci, 49, 732, 10.1167/iovs.07-0721 Wang, 2011, Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy, Cell Physiol Biochem, 27, 769, 10.1159/000330085 Eljarrat-Binstock, 2010, New techniques for drug delivery to the posterior eye segment, Pharm Res, 27, 530, 10.1007/s11095-009-0042-9 Saylor, 2009, Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review, Arch Ophthalmol, 127, 402, 10.1001/archophthalmol.2009.9 Lambiase, 2008, Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma, Proc Natl Acad Sci USA, 106, 13469, 10.1073/pnas.0906678106 Hernández, 2013, Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes, Diabetes, 62, 2569, 10.2337/db12-0926 Aiello, 2008, Targeting intraocular neovascularization and edema-one drop at a time, N Engl J Med, 359, 967, 10.1056/NEJMcibr0804551